Clinical Trial Update: Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) [Phase 3]

View source ↗

Summary

Phase 3 trial (CHIME 1) evaluating treatment of impulsive aggression in subjects with ADHD in conjunction with standard ADHD treatment has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Snippet

Sponsor: Supernus Pharmaceuticals, Inc. | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: COMPLETED | Results posted: 2022-11-01